Partnerships & Strategic Alliances

SHERIDAN, WYOMING - December 10, 2025 - A new collaboration between Deutsche Telekom, Fraunhofer IAIS and Kliniken der Stadt Köln is bringing AI agents directly into hospital trauma rooms, aiming to structure life-critical information in real time, ease documentation burdens, and ultimately improve outcomes for severely injured patients.

From Chaotic Trauma Room to Structured, Real-Time Overview

In a typical trauma room, up to ten physicians and nurses work under extreme time pressure while all medically relevant information is exchanged verbally. The partners are developing an AI-powered real-time display system that "listens" to team conversations during trauma simulations at Cologne's Merheim Hospital.

SHERIDAN, WYOMING - December 10, 2025 - Deutsche Telekom and OpenAI have entered a multi-year strategic collaboration to co-develop AI-powered products and experiences, positioning the European telecoms group to embed next-generation models across its customer channels, internal workflows and network operations at unprecedented scale.

Strategic Collaboration, Not a Typical Vendor Deal

Under the agreement, Deutsche Telekom will be among the first companies globally to gain early access to an alpha-phase OpenAI model. The partners will use this access to design new AI-powered services focused on communication and everyday productivity, with first pilots slated for the first quarter of 2026.

SHERIDAN, WYOMING - December 4, 2025 - Vortex Control Technologies (VCT) has signed a fleet-wide retrofit agreement with Norwegian to equip all Boeing 737-800 aircraft with its patented Finlet fuel-saving modification, aligning the Nordic carrier's cost discipline with a more aggressive sustainability strategy in short- and medium-haul aviation.

Aerodynamic retrofits move from trial to fleet standard

Under the new agreement, Norwegian will install VCT Finlets across its entire 737-800 fleet, following in the footsteps of early adopters such as Avelo Airlines, SunExpress and the U.S. Air Force. The deal marks a pivot from pilot programs to full-fleet deployment, signaling growing confidence among operators that incremental aerodynamic improvements can deliver material savings at scale.

SHERIDAN, WYOMING - December 3, 2025 - AGC Biologics is expanding its Cell Line Development Center of Excellence through a new partnership with ATUM, integrating the Leap-In Transposase® expression platform to help biopharma developers move monoclonal antibodies and complex next-generation biologics into the clinic faster and more cost-effectively.

New options for faster, more flexible cell line development

As pressure grows to launch high-value biologics at lower cost, drug sponsors are looking for cell line development (CLD) solutions that combine speed, robustness and scalability. AGC Biologics' collaboration with ATUM adds a modern transposase-based expression platform to its CLD toolkit, creating a menu of fit-for-purpose options for standard monoclonals, multi-specific antibodies and other complex molecules.

SHERIDAN, WYOMING - December 3, 2025 - AGC Biologics has signed a new manufacturing agreement with AAVantgarde Bio to produce dual-vector AAV gene therapies for Stargardt disease and retinitis pigmentosa, positioning its BravoAAV™ platform at the center of next-generation treatments for inherited retinal disorders with no approved therapies.

Dual-vector AAV platform targets previously "untreatable" retinal genes

Under the deal, AGC Biologics will provide GMP manufacturing for AAVantgarde's two clinical-stage candidates: AAVB-039 for Stargardt disease, the most common inherited form of macular degeneration in children and young adults, and AAVB-081 for retinitis pigmentosa caused by Usher syndrome type 1B. Both programs are in Phase 1/2 trials, with AAVB-039 being tested in the U.S., UK and Europe, and AAVB-081 representing the first-ever dual AAV gene therapy in an ocular indication.

SHERIDAN, WYOMING - December 3, 2025 - AGC Biologics has signed a strategic development and manufacturing agreement with Repair Biotechnologies to advance a novel mRNA therapeutic aimed at rapidly stabilizing and shrinking atherosclerotic plaques, addressing what both partners describe as the leading single cause of human mortality worldwide.

Targeting plaque biology in a high-burden cardiovascular market

The collaboration focuses on an mRNA-based therapy designed to stabilize and reduce atherosclerotic plaques in major blood vessels, directly tackling the root pathology behind heart attacks and strokes. Rupture of unstable plaque and subsequent thrombotic events account for an estimated 27% of all human deaths, underscoring the strategic importance of any technology capable of reversing or halting plaque progression.

SHERIDAN, WYOMING - December 3, 2025 - AGC Biologics is partnering with public benefit company Rarity PBC to bring a potentially life-saving gene therapy for Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) through commercial manufacturing and toward FDA approval, underscoring how CDMO collaborations are becoming central to translating academic breakthroughs into scalable rare disease treatments.

From transformational trials to a U.S. commercial pathway

Under the new agreement, AGC Biologics will provide end-to-end development and GMP manufacturing for Rarity's ex vivo autologous gene therapy RDP-101. If approved, RDP-101 would become the first gene therapy commercially available in the United States to reverse ADA-SCID, a rare inherited immunodeficiency that leaves infants dangerously exposed to severe, recurrent infections.

SHERIDAN, WYOMING - December 2, 2025 - Ricoh and Neat have signed a global partnership agreement to deliver integrated, high-end audiovisual solutions for modern workplaces worldwide, combining Neat's AI-driven video devices with Ricoh's AV Managed Services to enhance hybrid collaboration and workplace experience.

Master-level alliance to scale premium meeting experiences

Under the agreement, Neat, a global leader in professional AV and innovative video technology, and Ricoh, a global leading AV integrator, will collaborate at the highest tier of Neat's Global Partner Program-the Mastery level. The partnership is designed to expand Ricoh's portfolio of high-end meeting room solutions and make Neat-powered spaces more accessible across enterprises of all sizes.

SHERIDAN, WYOMING - November 28, 2025 - Farizon New Energy Commercial Vehicle Group is strengthening its position in the European commercial vehicle market with a new spare parts warehouse and a three-way strategic cooperation that aims to boost parts availability, fleet uptime and green logistics performance across the region.

Strategic Partnership Anchored in London

On 24 November 2025 in London, Farizon, Duvenbeck Logistics Group and AGN LEANWAY International Logistics, part of Amass Group, signed a strategic cooperation agreement to support mutually beneficial growth in European logistics operations. The agreement was signed by Cook Xue, CEO of Farizon International Company, Marco Nazzari, Chief Commercial Officer of Duvenbeck, and Peter Wenren, Chairman of AGN Leanway, and witnessed by Farizon Group CEO Mike Fan alongside senior management from all three companies.

SHERIDAN, WYOMING - November 28, 2025 - Chinese tire manufacturer Linglong Tire is stepping up its global brand-building strategy in the Automotive & Mobility sector with a new partnership agreement with the Chicago Bulls, leveraging one of the NBA's most iconic franchises to accelerate its visibility and market penetration across North and Latin America.

Global Sports Marketing as a Strategic Growth Lever

On 25 November 2025, Linglong Tire announced a global partnership with the Chicago Bulls, adding another high-profile sports collaboration to a portfolio that already includes European football giants Chelsea and Real Madrid. The deal underlines Linglong's ambition to position itself alongside internationally recognised sports brands as it competes for mindshare in mature and emerging tire markets.